Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, May 12 2016

Full Issue

Ryan Spotlights Opioid Package As Trump Meeting Looms

Although Washington's eyes are focused on an upcoming meeting between the speaker and the presumptive GOP nominee, Paul Ryan wanted to bring attention to the House's work this week at trying to pass 18 initiatives aimed at curbing the opioid epidemic. The White House, however, criticized the measures, saying they lack "substance."

The Boston Globe: Paul Ryan, Mass. Lawmakers Focus On Opioids In Shadow Of Trump

While the attention on Capitol Hill this week has focused on Donald Trump’s visit, a quieter — and potentially more substantive — conversation is underway in Congress to address the opioid addiction crisis sweeping the country. House Speaker Paul Ryan, after a morning meeting with Trump, is planning Thursday to continue pushing for passage of 18 initiatives to help stem the epidemic. (Jan, 5/12)

The Hill: White House Rips House GOP's Opioid Package

The White House on Wednesday blasted a lack of new funding in Republican legislation in the House to address the national opioid addiction crisis. White House press secretary Josh Earnest did not say whether President Obama would refuse to sign the bills. But he dismissed the measures, saying they lack “substance.” He noted that Speaker Paul Ryan’s (R-Wis.) office has complained that the series of 18 bills has not received widespread attention because of the raucous Republican presidential primary. (Fabian, 5/11)

Reuters: House Passes Bill To Aid Children Born Into Opioid Dependency

The House of Representatives on Wednesday unanimously passed legislation to improve safety planning for children who are born dependent on opioid drugs. A similar bill is pending in the Senate. It is one of more than a dozen new measures that are aimed at addressing a U.S. epidemic of addiction to pain pills and cheap heroin. (5/11)

The Huffington Post: The House Just Passed Opioid Legislation, But There’s Still A Fight Ahead

In the modern era of Congress, it’s a rare day when lawmakers vote on legislation actually intended to go to the president’s desk. It’s an even rarer occasion when that legislation is meant to help individuals battling opioid addiction — as is the case with the bills the House passed on Wednesday and the raft of legislation it’s expected to pass in the next few days. (Fuller, Grim and Cherkis, 5/11)

In other news from Capitol Hill —

The Wall Street Journal: Experts Decry Tying Medical Research Funds To FDA Standards Changes

Moves in Congress to link billions of dollars in new medical research funding to revised standards for drug and medical-device approvals are troubling some public-health experts, who say the combination makes it too easy for lawmakers to support lower patient-safety standards. These safety advocates say legislation to beef up research funding for the National Institutes of Health should be separated from product-approval changes at the Food and Drug Administration. (Burton, 5/12)

CQ Healthbeat: Senate Could Take Up Mental Health Bill Sooner Than Expected

Senate leaders are seeking lawmakers' input on whether to schedule a mental health bill for floor action between Memorial Day and the July Fourth recess, and several senators already are lobbying for consideration of their amendments. (Siddons, 5/11)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF